Where to Buy Sacubitril Valsartan Custom Manufacturer 2026

Sacubitril Valsartan Sodium — developed as LCZ696 and marketed under the brand name Entresto — is the angiotensin receptor neprilysin inhibitor (ARNI) that reshaped heart failure treatment. With generic entry moving closer, procurement teams, formulation developers, and CRO/CDMO partners are asking a practical question: where can a buyer find a custom manufacturer able to supply Sacubitril Valsartan and its full-chain intermediates at registration-grade quality, with documentation that holds up under global regulatory review?

This guide examines what that sourcing decision actually involves, which specifications matter, and how suppliers such as Shandong Tianming Pharmaceutical Group structure their offering.

Why the Search for a Sacubitril Valsartan Custom Manufacturer Is Time-Critical

The competitive clock is well understood across the industry. The US core patent for Sacubitril Valsartan Sodium expired in July 2023, and the China compound patent expires in 2026 — a "golden window" before generic entry that dozens of generic drug companies are racing to occupy. Each of those programs needs three things simultaneously: a qualified supplier, reliable batch consistency, and a cost structure that survives post-patent pricing pressure.

That combination is harder to secure than it first appears. Sacubitril Calcium, the advanced intermediate most programs depend on, must meet tight chiral and purity limits, and it must be available across laboratory small-batch, pilot scale-up, and commercial mass production. Splitting those stages across multiple vendors introduces the coordination cost and batch variability that delay filings and inflate procurement budgets.

Reading the Molecular Chain: What "Full-Chain" Really Means

A supplier worth shortlisting should be able to trace the entire synthesis ladder, not simply quote a final API. In the Sacubitril Valsartan route, that ladder begins with chiral starting materials and runs through several defined intermediates:

• Starting material CAS 1426129501 — N-[(1R)-2-[1,1′-Biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester, the chiral starting material for Sacubitril synthesis
• Starting material CAS 5717373 — Ethoxycarbonylmethylene triphenylphosphorane, the Wittig reagent used in the olefination step
• Intermediate CAS 1012341488 — (R,E)-5-([1,1′-Biphenyl]-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-pentenoic acid, the unsaturated intermediate formed by Wittig coupling
• Intermediate CAS 1012341502 — (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid, the saturated chiral intermediate obtained after hydrogenation
• Intermediate CAS 149690120 — (2R,4S)-Ethyl 5-([1,1′-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride, the deprotected chiral amine intermediate
• Advanced intermediate CAS 1369773396 — Sacubitril Calcium Salt, which also supports independent intellectual property new chemical entity development such as Sacubitril Alisartan Calcium
• API CAS 936623904 — Sacubitril Valsartan Sodium, the 1:1 molar ratio co-crystal of Sacubitril and Valsartan

Evaluating suppliers against this chain reveals an important distinction: vendors who hold only the final API force customers to coordinate several upstream sources, while a full-chain supplier eliminates that multi-supplier coordination cost and protects route consistency from the first step onward.

Quality Specifications That Withstand Regulatory Scrutiny

Purity claims are easy to make and harder to document. For Sacubitril Calcium, the reference standard to look for is individual impurity below 0.1% and chiral purity above 99.5%. Beyond those headline figures, a credible manufacturer should monitor the Sacubitril-to-Valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form — the attributes that determine whether a co-crystal API behaves consistently in formulation.

Documentation carries equal weight. Complete COA, MOA methodology, impurity profile studies, and stability data are what allow a customer to file DMF and CEP submissions globally, and structural confirmation documentation should be available for all products. A supplier that cannot supply these alongside the material adds months to a regulatory timeline.

Capacity, Equipment, and Delivery Reliability

Scale determines whether a supplier can follow a program from feasibility to launch. Relevant indicators include the number of coordinated production bases, reactor vessel count, annual production capacity, and the ability to supply from gram-level through ton-level. Physical handling also matters for these compounds: options such as cold chain for temperature-sensitive products, nitrogen-filled vacuum packaging for oxidation-sensitive products, and full logistics tracing with transport insurance are standard considerations for cardiovascular intermediates.

On timing, in-stock orders are typically delivered within 7–15 working days, covering order confirmation, quality review, packaging, and shipping. Made-to-order lead times depend on synthesis complexity, workshop scheduling, and raw material availability, with expedited production scheduling available for urgent projects.

How Shandong Tianming Pharmaceutical Group Structures Its Offering

Shandong Tianming Pharmaceutical Group, headquartered in Jinan, Shandong Province, operates an integrated R&D-production model as a National High-Tech Enterprise, supplying API, intermediates, and CMO/CDMO custom development and production solutions. Its predecessor, Shandong Sihuan Pharmaceutical Co., Ltd., was founded in 2010, with the group formally established in 2020.

Its full-chain product matrix covers N-1 to N-5 intermediates for flagship molecules including Sacubitril Valsartan Sodium, Orforglipron, and Finerenone — 98 products and services in total. The group runs two R&D centers, in Jinan and Nanjing, spanning over 6,000 square meters of laboratory space with more than 100 R&D personnel and RMB 40+ million in professional R&D and testing equipment including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments. It holds 20 invention patents and 40 utility model patents, and invests above 10% of annual revenue in R&D, against an industry average around 5%.

Three production bases — Shandong Sihuan in Dezhou, Jining Tianming in Jining, and Guangxi Tianming in Hechi — provide over 160 reactor vessels and annual production capacity in the hundreds of tons, with gram-level to ton-level supply and elastic capacity reserves. Two overseas business entities in India and Bangladesh support international customers across 30+ countries and regions, alongside more than 2,000 cooperative customers.

A Practical Checklist for Vetting Suppliers

1. Does the supplier cover the full N-1 to N-5 ladder, or only the final API?
2. Are impurity profiles, COA, MOA methodology, and stability data available to support DMF and CEP filings?
3. Can the supplier demonstrate gram-level to ton-level flexibility without changing routes?
4. What are the stated delivery windows for in-stock and made-to-order material?
5. Is the technical support model defined — for example, a 1-on-1 account manager plus technical engineer pairing, routine issues addressed within 2 hours, and complex issues resolved in a written report within 24 hours?

Moving From Sample to Commercial Supply

Most cardiovascular programs begin with gram-level or hundred-gram samples for route validation, move to pilot batches, and then scale to commercial volume. A supplier offering standard product sales alongside CMO/CDMO custom development, custom synthesis, process optimization, and impurity customization can carry a program through every one of those stages. For buyers weighing where to source Sacubitril Valsartan and its intermediates, the deciding factors are rarely price alone — they are chain completeness, documented quality, and the capacity to scale without interruption.